— Know what they know.
Not Investment Advice

Financial News

Sentiment 43.1 5419 articles 2840 bullish 1163 bearish Full Index →
What's Behind The Drop In Reviva Pharmaceuticals Stock?

What's Behind The Drop In Reviva Pharmaceuticals Stock?

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) are tumbling after the company announced the pricing of its $10 million public offering...
Intel Teams With Versa To Bring Super-Fast AI Tools Directly

Intel Teams With Versa To Bring Super-Fast AI Tools Directly To Local Businesses

Versa is teaming up with Intel Corp (NASDAQ:INTC) to bring AI-powered tools closer to where businesses actually operate, aiming to improve speed,...
📰

Aveanna (AVAH) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.Thursday, March 19, 2026, at 10 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading
Move Over Meta, Microsoft — Constellation, NextEra Hit Big T

Move Over Meta, Microsoft — Constellation, NextEra Hit Big Tech Valuations In 2026's Weirdest Trade

The stock market's strangest trend of 2026 might be hiding in the utility sector. Constellation Energy Corp. (NASDAQ:CEG) and NextEra Energy...
AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock?

AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock?

Amgen stock holds above key SMAs as strong drug sales, biosimilars, and MariTide pipeline momentum offset looming patent losses and pricing headwinds.
AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock?

AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock?

Amgen stock holds above key SMAs as strong drug sales, biosimilars, and MariTide pipeline momentum offset looming patent losses and pricing headwinds.
AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock?

AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock?

Amgen stock holds above key SMAs as strong drug sales, biosimilars, and MariTide pipeline momentum offset looming patent losses and pricing headwinds.
AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock?

AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock?

Amgen stock holds above key SMAs as strong drug sales, biosimilars, and MariTide pipeline momentum offset looming patent losses and pricing headwinds.
📰

Novo Nordisk: Wegovy HD (semaglutide 7.2mg) approved by US FDA ($NVO $HIMS 🚀)

https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916516   submitted by   ...
📰

Novo Nordisk: Wegovy HD (semaglutide 7.2mg) approved by US FDA ($NVO $HIMS 🚀)

https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916516   submitted by   ...
J&J Expands New Drug Portfolio With Icotyde's FDA Approval

J&J Expands New Drug Portfolio With Icotyde's FDA Approval

J&J wins FDA nod for Icotyde, a once-daily oral psoriasis pill, boosting its new drugs portfolio and challenging injectable treatments in a key...
J&J Expands New Drug Portfolio With Icotyde's FDA Approval

J&J Expands New Drug Portfolio With Icotyde's FDA Approval

J&J wins FDA nod for Icotyde, a once-daily oral psoriasis pill, boosting its new drugs portfolio and challenging injectable treatments in a key...
J&J Expands New Drug Portfolio With Icotyde's FDA Approval

J&J Expands New Drug Portfolio With Icotyde's FDA Approval

J&J wins FDA nod for Icotyde, a once-daily oral psoriasis pill, boosting its new drugs portfolio and challenging injectable treatments in a key...
The Great Magnificent 7 Breakup: Nvidia Stands Tall While Te

The Great Magnificent 7 Breakup: Nvidia Stands Tall While Tesla, Microsoft Stumble And Fall

The much-vaunted Magnificent Seven stocks are starting to look a lot less magnificent as a group. In 2026, the market's favorite mega-cap tech...
Gold Tumbles Over 6%; Accenture Earnings Top Views

Gold Tumbles Over 6%; Accenture Earnings Top Views

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 150 points on Thursday. The Dow traded down 0.81% to...
Gold Tumbles Over 6%; Accenture Earnings Top Views

Gold Tumbles Over 6%; Accenture Earnings Top Views

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 150 points on Thursday. The Dow traded down 0.81% to...
Stellantis EVs Gain Tesla Supercharger Access Across North A

Stellantis EVs Gain Tesla Supercharger Access Across North America

Stellantis N.V. (NYSE:STLA) said Thursday it is expanding fast-charging access in North America by enabling its battery-electric vehicles (BEVs) to...
📰

Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know

Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
📰

Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why

Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects....
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Wh

Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why

XENE shares gain 20% in 3 months as positive phase III data for epilepsy drug azetukalner and pipeline progress boost outlook and investor confidence.
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Wh

Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why

XENE shares gain 20% in 3 months as positive phase III data for epilepsy drug azetukalner and pipeline progress boost outlook and investor confidence.
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Wh

Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why

XENE shares gain 20% in 3 months as positive phase III data for epilepsy drug azetukalner and pipeline progress boost outlook and investor confidence.
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Wh

Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why

XENE shares gain 20% in 3 months as positive phase III data for epilepsy drug azetukalner and pipeline progress boost outlook and investor confidence.
Sarepta To Request FDA For Traditional Approvals For Duchenn

Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs

Sarepta Therapeutics Inc. (NASDAQ:SRPT) shares are down during Thursday’s session following a regulatory update regarding its treatments for...
📰

ALGN or WST: Which Is the Better Value Stock Right Now?

ALGN vs. WST: Which Stock Is the Better Value Option?
📰

ALGN or WST: Which Is the Better Value Stock Right Now?

ALGN vs. WST: Which Stock Is the Better Value Option?
📰

BTSG or ALHC: Which Is the Better Value Stock Right Now?

BTSG vs. ALHC: Which Stock Is the Better Value Option?
📰

BTSG or ALHC: Which Is the Better Value Stock Right Now?

BTSG vs. ALHC: Which Stock Is the Better Value Option?
The Race to Shield Global Infrastructure from the Coming Qua

The Race to Shield Global Infrastructure from the Coming Quantum Threat

Issued on behalf of Quantum Secure Encryption Corp. VANCOUVER, BC, March 19, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — Think of it as a...
Eli Lilly Says Experimental Diabetes Drug Shows Weight Loss

Eli Lilly Says Experimental Diabetes Drug Shows Weight Loss Of 17%

Eli Lilly and Co (NYSE:LLY) shares are down on Thursday. The company released news regarding its investigational drug, retatrutide, which has shown...
📰

Nextech Trims Kymera at a Recent High — think Foolishly before acting.

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.
Embecta Rallies After UK Firm Deal Worth $200 Million

Embecta Rallies After UK Firm Deal Worth $200 Million

Embecta Corp. (NASDAQ:EMBC) shares are up on Thursday after the company agreed to acquire Owen Mumford Holdings Limited. This strategic move aims to...
What's Going On With Ondas Stock Thursday?

What's Going On With Ondas Stock Thursday?

Ondas Inc. (NASDAQ:ONDS) said Thursday that its Sentrycs unit deployed its Cyber-over-RF technology at the World Economic Forum 2026 in Davos,...
What's Going On With Tilray Brands Stock?

What's Going On With Tilray Brands Stock?

Tilray Brands (NASDAQ:TLRY) announced an expansion of its medical cannabis portfolio in Australia, despite a challenging market environment. The...
What's Going On With Tilray Brands Stock?

What's Going On With Tilray Brands Stock?

Tilray Brands (NASDAQ:TLRY) announced an expansion of its medical cannabis portfolio in Australia, despite a challenging market environment. The...
📰

DarioHealth (DRIO) Q4 2025 Earnings Transcript

Image source: The Motley Fool.Thursday, March 19, 2026 at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading
📰

Medtronic (MDT) Down 11.5% Since Last Earnings Report: Can It Rebound?

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰

Medtronic (MDT) Down 11.5% Since Last Earnings Report: Can It Rebound?

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰

Why Is Labcorp (LH) Down 4.6% Since Last Earnings Report?

Labcorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰

Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰

Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰

Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰

Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰

Why Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report?

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰

Why Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report?

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
« Prev 1 74 75 76 77 78 82 Next »

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms